An interventional study of Misoprostol 400 micrograms and Misoprostol 800 micrograms in Termination, sponsored by Hormozgan University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to female participants. Per ClinicalTrials.gov, last updated 2012-10-02.
Sponsored by Hormozgan University of Medical Sciences · Not applicable, Interventional, and Treatment
The aim of this study is to compare two misoprostol regimen in pregnancy termination.
Studies on determining the optimal dosage for misoprostol in pregnancy termination are continuing and still there is no evidence for ideal misoprostol regimen for pregnancy termination. The aim of this study is to compare two misoprostol regimen in pregnancy termination.
Hormozgan University of Medical Sciences is the lead sponsor of 23 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
400 micrograms misoprostol each 6 hours for 8 dose
Drug: Misoprostol 400 micrograms
800 micrograms misoprostol each 12 hours for 4 dose
Drug: Misoprostol 800 micrograms
Misoprostol 400 micrograms each 6 hours for 8 dose
Also known as: Cytotec
Misoprostol 800 micrograms each 12 hours for 4 doses
Also known as: Cytotec
Abortion
After 48 hours after treatment each patient is assessed for abortion. Patients are devided into three groups including complete, partial or no abortion.
Time frame: 48 hours after treatment
Duration of abortion
Duration of abortion Form the begining of treatment to complete abortion
Time frame: Form the begining of treatment to complete abortion
Adverse Effects
including nausea, vomiting, fever and chill, diarhea, abdominal cramp, skin rash
Time frame: 48 hours after treatment
Need for surgery
Dilatation \& cartage
Time frame: 48 hours after treatment
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hormozgan University of Medical Sciences